Department of Psychology, Syracuse University, Syracuse, New York.
Department of Anesthesiology, Perioperative and Pain Medicine, Brigham & Women's Hospital, Boston, Massachusetts.
J Pain. 2023 Feb;24(2):345-355. doi: 10.1016/j.jpain.2022.09.019. Epub 2022 Oct 12.
Benzodiazepines (BZDs), a class of sedative-hypnotic medications, generated concern as their popularity grew, with particular alarm regarding elevated rates of BZD use among chronic pain populations. Consistent with negative reinforcement/motivational models of substance use, desire for pain alleviation may motivate BZD use. Yet, little is known about relations between pain and addiction-relevant BZD use processes. This cross-sectional survey study aimed to: a) test associations between pain intensity and clinically relevant BZD use patterns, and b) examine the role of pain catastrophizing in hypothesized pain-BZD relations. Participants included 306 adults with chronic musculoskeletal pain and a current BZD prescription who completed an online survey study (M = 38.7, 38.9% female). Results indicated that pain intensity was positively associated with past-month BZD use frequency, BZD dependence severity, and likelihood of endorsing BZD misuse behaviors (ps < .05). Pain catastrophizing was positively associated with BZD dependence/likelihood of BZD misuse, covarying for pain intensity (P < .05). These findings build upon an emerging literature by highlighting positive covariation of pain intensity and pain catastrophizing with addiction-relevant BZD use behaviors. Results underscore the need to further investigate high-risk BZD use among individuals with chronic pain, with and without concurrent opioid use, to inform prevention/intervention efforts. PERSPECTIVE: This article presents findings on cross-sectional associations of pain intensity and pain catastrophizing with clinically relevant benzodiazepine (BZD) use outcomes, including dependence and misuse, among individuals with chronic pain. Findings help elucidate the higher burden of BZD misuse/dependence in chronic pain populations and suggest that pain relief may be a common, yet under recognized, self-reported motivation for taking BZDs.
苯二氮䓬类药物(BZDs)是一类镇静催眠药物,随着其受欢迎程度的提高,人们开始关注其使用问题,尤其是在慢性疼痛人群中 BZD 使用率升高的问题。根据物质使用的负强化/动机模型,缓解疼痛的愿望可能会促使人们使用 BZD。然而,人们对疼痛与成瘾相关的 BZD 使用过程之间的关系知之甚少。这项横断面调查研究旨在:a)检验疼痛强度与临床上相关的 BZD 使用模式之间的关系,b)检验疼痛灾难化在假设的疼痛-BZD 关系中的作用。研究对象包括 306 名患有慢性肌肉骨骼疼痛且目前正在服用 BZD 处方的成年人,他们完成了一项在线调查研究(M=38.7,38.9%为女性)。结果表明,疼痛强度与过去一个月 BZD 使用频率、BZD 依赖严重程度和 BZD 滥用行为的可能性呈正相关(p<.05)。疼痛灾难化与 BZD 依赖/滥用 BZD 的可能性呈正相关,且与疼痛强度共变(P<.05)。这些发现是对现有文献的补充,突出了疼痛强度和疼痛灾难化与成瘾相关的 BZD 使用行为之间的正相关性。结果强调需要进一步研究慢性疼痛患者(包括同时使用阿片类药物和不使用阿片类药物的患者)中高风险 BZD 使用情况,以提供预防/干预措施的依据。观点:本文介绍了疼痛强度和疼痛灾难化与慢性疼痛患者中与临床相关的苯二氮䓬类药物(BZD)使用结果(包括依赖和滥用)的横断面关联的研究结果。研究结果有助于阐明慢性疼痛人群中 BZD 滥用/依赖的负担更高,并表明缓解疼痛可能是服用 BZD 的常见但未被认识到的自我报告动机。